Already a member?
Login
Become a member
Register
About
About PCSK9 Forum
Editorial Board
Mission Statement
Home
About PCSK9
What are PCSK9 inhibitors?
Why are new treatments needed?
Which patients may benefit?
Expert Meetings
News
News
Meeting Reports
Commentary
Hot topics
From the Editors
Questions of the Month
Slides
Slide Resource Programme
Slides by Editorial Board
Trials
Videos
Resources
Trials
Slides by Editorial Board
Events
Videos
Webcasts
Guidelines & Consensus Guidance
Article Archive
Contact
⇒ Main Menu
About
– About PCSK9 Forum
– Editorial Board
– Mission Statement
– Home
– What are PCSK9 inhibitors?
– Why are new treatments needed?
– Which patients may benefit?
Expert Meetings
News
– News
– Meeting Reports
– Hot topics
– From the Editors
– Questions of the Month
Slides
– Slide Resource Programme
– Slides by Editorial Board
Trials
Videos
Resources
– Trials
– Slides by Editorial Board
– Events
– Videos
– Webcasts
– Guidelines & Consensus Guidance
– Article Archive
Contact
News
LIBerate-HeFH: Lerodalcibep reduces LDL-C in HeFH
ORION-8: Inclisiran shows efficacy and safety beyond six years
Phase 3 data show benefits of alirocumab in children with HeFH
REMAIN-1: Recaticimab significantly reduces LDL-C even with infrequent dosing
Phase 3 programme for MK-0616 gets underway
MK-0616 – How near is an oral PCSK9i?
Latest News Updates
News on PCSK9 Forum: Real-world use of PCSK9 inhibitors
Posted on
30 April 2019
|
Related content